Wall Street Price Targets Point to Upside for TMO, DY, CR; Independent Firm Flags TMO Valuation

Wall Street analysts project double-digit upside for Thermo Fisher Scientific (NYSE:TMO), Dycom (NYSE:DY), and Crane (NYSE:CR) based on consensus price targets, though independent research provider StockStory raises a caution on Thermo Fisher’s valuation. Thermo Fisher’s consensus target of $611.56 implies a 24% return from its June 1 closing price of $493.30. However, StockStory points to the stock’s forward P/E of 19.2x as a potential concern. The firm notes that analysts rarely issue sell ratings, which may inflate consensus optimism. Dycom’s consensus target stands at $625.64—24.1% above the $504 share price—while the stock trades at 31.5x forward earnings. Crane’s target of $219.67 represents a 20.1% premium to its $182.97 price, at 26x forward P/E. No additional context was provided for the bullish views on these two companies.